Featured News
Candidate for First Human Hookworm Vaccine Enters Phase 1 Clinical Trial in Brazil
WASHINGTON, DC-- Jan. 19, 2012--The Sabin Vaccine Institute (Sabin) today announced the start of a Phase 1 clinical trial of its Na-GST-1 antigen, a candidate for the first human hookworm vaccine. The trial is a major milestone for the vaccine product development partnership (PDP) headquartered at Sabin. This trial advances Sabin’s goal to develop a safe, efficacious and low-cost vaccine to reduce the global burden of human hookworm, which infects nearly 600 million people worldwide.
Featured News
Major Campaign Launched to Eliminate Seven Diseases by 2020
The END7 Campaign is dedicated to building awareness of diseases that infect more than one billion people worldwide WASHINGTON, DC —January 10, 2012 – Launched today, the END7 campaign is dedicated to eliminating seven major neglected tropical diseases (NTDs) as a public health threat to poor communities by the end of 2020. NTDs infect one in six people worldwide, including 500 million children, and carry a higher health burden than malaria and tuberculosis.
We’re scientists. We’re researchers. And we’re advocates for a world free of needless suffering.
We develop new vaccines to combat neglected and global health threats, while simultaneously ensuring that existing and effective treatments get into the hands of people in need. We are particularly committed to saving lives in the world’s areas of greatest neglect, poverty, and destitution. We build bridges between leaders in science, academia, industry and government to conduct critical research to catalyze these solutions.
We’re a non-profit 501(c)(3) organization with generous support from the Bill & Melinda Gates Foundation and other organizations and individuals dedicated to our mission of reducing human suffering from vaccine preventable and neglected tropical diseases. Everyday, our work is lifting people out of poverty, improving and saving lives.
